Browse News
Filter News
Found 769,185 articles
-
Partnership seeks to identify novel therapeutic molecules to address diseases with high unmet patient needs. It’s the second target discovery company to link with BI in the last month. -
Takeda plans to cut about 186 staff members across Massachusetts, beginning in early July. -
The German biotech is trying to deepen its pipeline in cancer and other infectious diseases as COVID-19 markets contract and the international public health emergency comes to an end. -
Weeks after announcing a CEO shake-up and slightly decreased Q1 revenues, BMS plans to cut 48 staff members from its Princeton, NJ, facility. -
After a brief slump, interest in ADCs is at an all-time high, highlighted by a handful of recent multi-million- and billion-dollar acquisitions. -
Despite multiple therapeutics approved to treat localized symptoms, there are currently no systemic therapies on the market for Sjogren’s syndrome. -
The FDA's agenda includes an advisory committee meeting for Sarepta's delandistrogene moxeparvovec, which, if approved, would become the first gene therapy for Duchenne muscular dystrophy. -
The FDA’s new guidance on decentralized clinical trials clarifies how investigators and trial sponsors can use digital health technologies and involve primary healthcare practitioners. -
Legend Biotech Corporation Announces Pricing of Registered Direct Offering of $350 Million of American Depositary Shares
5/8/2023
Legend Biotech Corporation today announced that it has agreed to sell 5,468,750 American Depositary Shares (“ADSs”), each representing two ordinary shares of the Company, at a price of $64.00 per ADS, in a registered direct offering.
-
Incyte Strengthens Research & Development Efforts Appointing Pablo J. Cagnoni, M.D. to New Leadership Role
5/8/2023
Dr. Cagnoni joins Incyte’s Executive Team as President and Head of Research & Development.
-
NLS Pharmaceutics Appoints Keith Harrison Dewedoff as Interim Chief Financial Officer
5/8/2023
NLS Pharmaceutics Ltd. today announced that Keith Harrison Dewedoff has been appointed to the position of Interim Chief Financial Officer.
-
Virogentics Inc. Announces Pilot Clinical Trial of ITV-1 at National Center for Endocrinology in Bulgaria and Expansion of Nutraceutical Line
5/8/2023
Enzolytics, Inc. announced that the Company's wholly owned subsidiary, Virogenetics (VIRO), will be conducting a pilot clinical trial test for the state owned Bulgarian National Center for Endocrinology to gauge the effectiveness of the ITV-1 immunotherapy on Diabetes.
-
Solarea Bio Announces First Close of Series B Financing Round
5/8/2023
Solarea Bio announced today a first closing of $15m in a Series B financing led by S2G Ventures with continued participation of Bold Capital Partners, Viking Global Investors, and GG 1978 SICAF SIF.
-
New Data from Phase 1/2 Trial of INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis Presented at ABEA during COSM 2023
5/8/2023
INOVIO presented new data from a Phase 1/2 trial of INO-3107 (NCT:04398433) for the treatment of HPV 6 and HPV 11-associated Recurrent Respiratory Papillomatosis (RRP) on May 5th as part of the scientific program of the American Broncho-Esophagological Association (ABEA) at the Combined Otolaryngology Spring Meetings (COSM) in Boston, Massachusetts.
-
Recursion Provides Business Updates and Reports First Quarter 2023 Financial Results
5/8/2023
Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today reported business updates and financial results for its first quarter ending March 31, 2023.
-
Krystal Biotech Announces First Quarter 2023 Financial Results and Operational Highlights
5/8/2023
Krystal Biotech, Inc. today reported financial results and key operational progress updates for the first quarter ended March 31, 2023.
-
Temple Therapeutics Reveals Breakthrough Findings on Ovarian Cancer at AACR 2023
5/8/2023
Temple Therapeutics presented new in vitro and in vivo data on TTX335o, the first drug candidate from the company’s platform that won the Eurostar Eureka peer-reviewed grant process in 2019 for ovarian cancer.
-
Life Biosciences and Forge Biologics Announce cGMP Manufacturing Partnership to Advance Development of Novel Gene Therapies for Aging-Related Diseases
5/8/2023
Life Biosciences and Forge Biologics today announced a manufacturing partnership to help advance Life Bio’s partial epigenetic reprogramming platform to address aging-related diseases, including its lead program targeting ophthalmic indications.
-
Natera Announces New Publication from I-SPY2 Trial Reinforcing Clinical Utility of Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting
5/8/2023
Natera, Inc. today announced the publication of a new paper 1 in Cancer Cell from the I-SPY2 trial, highlighting the prognostic and predictive utility of Natera’s personalized and tumor-informed, molecular residual disease (MRD) test, Signatera, in locally advanced breast cancer patients receiving neoadjuvant chemotherapy (NAC, treatment before surgery).
-
AceLink Therapeutics Appoints Pedro Huertas, M.D., Ph.D., as Chief Medical Officer
5/8/2023
AceLink Therapeutics, Inc. today announced the appointment of Pedro Huertas, M.D., Ph.D., as Chief Medical Officer (CMO).